The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases

British Journal of Haematology

Volumn 149, Issue 1, 2010, Pages 3-13

  Cooper, Nichola ^a   Arnold, Donald M ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Hepatitis B; Infections; ITP; PML; Rituximab

Indexed keywords

AUTOANTIBODY; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXORUBICIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HISTONE ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; LAMIVUDINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PREDNISONE; RITUXIMAB; RO ANTIBODY; TETANUS TOXOID; THROMBOCYTE ANTIBODY; VINCRISTINE;

ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANCA ASSOCIATED VASCULITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNE SKIN DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROVIRUS INFECTION; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFLUENZA; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LIVER FAILURE; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOMA; MEMORY CELL; MONOTHERAPY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYCOSIS; MYOSITIS; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PARVOVIRUS INFECTION; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REPEATED DRUG DOSE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SIDE EFFECT; SJOEGREN SYNDROME; SKIN DISEASE; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TETANUS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; VACCINATION; VASCULITIS; VIRUS INFECTION; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; OPPORTUNISTIC INFECTIONS;

EID: 77949404018     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08076.x     Document Type: Review

References (108)

1. Aksoy, S., Harputluoglu, H., Kilickap, S., Dede, D.S., Dizdar, O., Altundag, K. & Barista, I. (2007) Rituximab-related viral infections in lymphoma patients. Leukaemia & Lymphoma, 48, 1307-1312.
2. Albert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S., Tsai, D., Pullman-Mooar, S., Barnack, F., Striebich, C., Looney, R.J., Prak, E.T., Kimberly, R., Zhang, Y. & Eisenberg, R. (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Annals of the Rheumatic Diseases, 67, 1724-1731.
3. Anolik, J.H., Campbell, D., Felgar, R.E., Young, F., Sanz, I., Rosenblatt, J. & Looney, R.J. (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis and Rheumatism, 48, 455-459.
4. Arnold, D.M., Dentali, F., Crowther, M.A., Meyer, R.M., Cook, R.J., Sigouin, C., Fraser, G.A., Lim, W. & Kelton, J.G. (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of Internal Medicine, 146, 25-33.
5. Bearden, C.M., Agarwal, A., Book, B.K., Vieira, C.A., Sidner, R.A., Ochs, H.D., Young, M. & Pescovitz, M.D. (2005) Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. American Journal of Transplantation, 5, 50-57.
6. Bennett, C.M., Rogers, Z.R., Kinnamon, D.D., Bussel, J.B., Mahoney, D.H., Abshire, T.C., Sawaf, H., Moore, T.B., Loh, M.L., Glader, B.E., McCarthy, M.C., Mueller, B.U., Olson, T.A., Lorenzana, A.N., Mentzer, W.C., Buchanan, G.R., Feldman, H.A. & Neufeld, E.J. (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 107, 2639-2642.
7. + T cell activation in mice. Proceedings of the National Academy of Sciences of the United States of America, 104, 20878-20883.
8. Byrd, J.C., Kitada, S., Flinn, I.W., Aron, J.L., Pearson, M., Lucas, D. & Reed, J.C. (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 99, 1038-1043.
9. Calabrese, L.H. & Molloy, E.S. (2008) Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Annals of the Rheumatic Diseases, 67(Suppl 3), iii64-iii65.
10. Cambridge, G., Leandro, M.J., Teodorescu, M., Manson, J., Rahman, A., Isenberg, D.A. & Edwards, J.C. (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis and Rheumatism, 54, 3612-3622.
11. Carson, K.R., Evens, A.M., Richey, E.A., Habermann, T.M., Focosi, D., Seymour, J.F., Laubach, J., Bawn, S.D., Gordon, L.I., Winter, J.N., Furman, R.R., Vose, J.M., Zelenetz, A.D., Mamtani, R., Raisch, D.W., Dorshimer, G.W., Rosen, S.T., Muro, K., Gottardi-Littell, N.R., Talley, R.L., Sartor, O., Green, D., Major, E.O. & Bennett, C.L. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 113, 4834-4840.
12. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754-758.
13. Cattaneo, C., Spedini, P., Casari, S., Re, A., Tucci, A., Borlenghi, E., Ungari, M., Ruggeri, G. & Rossi, G. (2006) Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leukaemia & Lymphoma, 47, 1013-1017.
14. Christensen, S.R. & Shlomchik, M.J. (2007) Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Seminars in Immunology, 19, 11-23.
15. Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., Keystone, E.C., Loveless, J.E., Burmester, G.R., Cravets, M.W., Hessey, E.W., Shaw, T. & Totoritis, M.C. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism, 54, 2793-2806.
16. Coiffier, B. (2006) Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis. Cancer Investigation, 24, 548-552.
17. Cooper, N., Feuerstein, M., McFarland, J., Milligan, L., Cunningham-Rundles, S. & Bussel, J.B. (2002) Investigating the0020mechanism of action of rituximab, an anti-CD20 monoclonal antibody in adults with immune thrombocytopenic purpura. Blood (ASH Annual Meeting Abstracts), 100 Abstract 1860.
18. Cooper, N., Stasi, R., Cunningham-Rundles, S., Feuerstein, M.A., Leonard, J.P., Amadori, S. & Bussel, J.B. (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology, 125, 232-239.
19. Cooper, N., Davies, E.G. & Thrasher, A.J. (2009) Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. British Journal of Haematology, 146, 120-122.
20. Cragg, M.S. & Glennie, M.J. (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood, 103, 2738-2743.
21. Dhand, S. & Bahrain, H. (2008) Rituximab-induced severe acute thrombocytopenia: a case report and review of literature. Cancer Investigation, 26, 913-915.
22. Durand, C.A., Hartvigsen, K., Fogelstrand, L., Kim, S., Iritani, S., Vanhaesebroeck, B., Witztum, J.L., Puri, K.D. & Gold, M.R. (2009) Phosphoinositide 3-kinase p110delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. Journal of Immunology, 183, 5673-5684.
23. Edwards, J.C. & Cambridge, G. (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford), 40, 205-211.
24. Edwards, J.C. & Cambridge, G. (2005) Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford), 44, 151-156.
25. Edwards, J.C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D.R., Stevens, R.M. & Shaw, T. (2004a) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine, 350, 2572-2581.
26. Edwards, J.C., Leandro, M.J. & Cambridge, G. (2004b) B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheumatic Diseases Clinics of North America, 30, 393-403, viii.
27. Edwards, J.C., Cambridge, G. & Leandro, M.J. (2006) B cell depletion therapy in rheumatic disease. Best Practice & Research. Clinical Rheumatology, 20, 915-928.
28. Einfeld, D.A., Brown, J.P., Valentine, M.A., Clark, E.A. & Ledbetter, J.A. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO Journal, 7, 711-717.
29. Ferraro, A.J., Drayson, M.T., Savage, C.O. & MacLennan, I.C. (2008) Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. European Journal of Immunology, 38, 292-298.
30. Feuchtenberger, M., Muller, S., Roll, P., Waschbisch, A., Schafer, A., Kneitz, C., Wiendl, H. & Tony, H.P. (2008) Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis. The Open Rheumatology Journal, 2, 81-88.
31. Glennie, M.J., French, R.R., Cragg, M.S. & Taylor, R.P. (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology, 44, 3823-3837.
32. Godeau, B., Porcher, R., Fain, O., Lefrere, F., Fenaux, P., Cheze, S., Vekhoff, A., Chauveheid, M.P., Stirnemann, J., Galicier, L., Bourgeois, E., Haiat, S., Varet, B., Leporrier, M., Papo, T., Khellaf, M., Michel, M. & Bierling, P. (2008) Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood, 112, 999-1004.
33. Gong, Q., Ou, Q., Ye, S., Lee, W.P., Cornelius, J., Diehl, L., Lin, W.Y., Hu, Z., Lu, Y., Chen, Y., Wu, Y., Meng, Y.G., Gribling, P., Lin, Z., Nguyen, K., Tran, T., Zhang, Y., Rosen, H., Martin, F. & Chan, A.C. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. Journal of Immunology, 174, 817-826.
34. Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F. & Tedder, T.F. (2006) Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. Journal of Experimental Medicine, 203, 743-753.
35. Hanbali, A. & Khaled, Y. (2009) Incidence of hepatitis B reactivation following Rituximab therapy. American Journal of Hematology, 84, 195.
36. Hassan, R., Williams-Gould, J., Watson, T., Pai-Scherf, L. & Pastan, I. (2004) Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clinical Cancer Research, 10, 16-18.
37. Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., Langer-Gould, A. & Smith, C.H. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine, 358, 676-688.
38. Herlands, R.A., Christensen, S.R., Sweet, R.A., Hershberg, U. & Shlomchik, M.J. (2008) T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity, 29, 249-260.
39. Horwitz, S.M., Negrin, R.S., Blume, K.G., Breslin, S., Stuart, M.J., Stockerl-Goldstein, K.E., Johnston, L.J., Wong, R.M., Shizuru, J.A. & Horning, S.J. (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 103, 777-783.
40. Hoyer, B.F., Manz, R.A., Radbruch, A. & Hiepe, F. (2005) Long-lived plasma cells and their contribution to autoimmunity. Annals of the New York Academy of Sciences, 1050, 124-133.
41. Hu, C.Y., Rodriguez-Pinto, D., Du, W., Ahuja, A., Henegariu, O., Wong, F.S., Shlomchik, M.J. & Wen, L. (2007) Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. Journal of Clinical Investigation, 117, 3857-3867.
42. Kamar, N., Milioto, O., Puissant-Lubrano, B., Esposito, L., Pierre, M.C., Mohamed, A.O., Lavayssiere, L., Cointault, O., Ribes, D., Cardeau, I., Nogier, M.B., Durand, D., Abbal, M., Blancher, A. & Rostaing, L. (2009) Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. American Journal of Transplantation. doi:10.1111/j.1600-6143.2009.02785.x.
43. Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313, 670-673.
44. Kaplan, L.D., Lee, J.Y., Ambinder, R.F., Sparano, J.A., Cesarman, E., Chadburn, A., Levine, A.M. & Scadden, D.T. (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 106, 1538-1543.
45. Keystone, E., Fleischmann, R., Emery, P., Furst, D.E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., Udell, J., Cravets, M.W., Agarwal, S., Cooper, S. & Magrini, F. (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis and Rheumatism, 56, 3896-3908.
46. van der Kolk, L.E., Baars, J.W., Prins, M.H. & van Oers, M.H. (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood, 100, 2257-2259.
47. Lai, G.G., Lim, S.T., Tao, M., Chan, A., Li, H. & Quek, R. (2009) Lateonset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. American Journal of Hematology, 84, 414-417.
48. Larrar, S., Guitton, C., Willems, M. & Bader-Meunier, B. (2006) Severe hematological side effects following Rituximab therapy in children. Haematologica, 91, ECR36.
49. Leandro, M.J., Edwards, J.C. & Cambridge, G. (2002a) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Annals of the Rheumatic Diseases, 61, 883-888.
50. Leandro, M.J., Edwards, J.C., Cambridge, G., Ehrenstein, M.R. & Isenberg, D.A. (2002b) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis and Rheumatism, 46, 2673-2677.
51. Leandro, M.J., Cambridge, G., Edwards, J.C., Ehrenstein, M.R. & Isenberg, D.A. (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford), 44, 1542-1545.
52. Leandro, M.J., Cambridge, G., Ehrenstein, M.R. & Edwards, J.C. (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis and Rheumatism, 54, 613-620.
53. Leandro, M.J., Cooper, N., Cambridge, G., Ehrenstein, M.R. & Edwards, J.C. (2007) Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford), 46, 29-36.
54. Liang, R. (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood, 113, 3147-3153.
55. Lim, S.H., Esler, W.V., Zhang, Y., Zhang, J., Periman, P.O., Burris, C. & Townsend, M. (2008) B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leukaemia & Lymphoma, 49, 152-153.
56. Lin, P.C., Hsiao, L.T., Poh, S.B., Wang, W.S., Yen, C.C., Chao, T.C., Liu, J.H., Chiou, T.J. & Chen, P.M. (2007) Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Annals of Hematology, 86, 95-100.
57. Lok, A.S. & McMahon, B.J. (2004) Chronic hepatitis B: update of recommendations. Hepatology, 39, 857-861.
58. Looney, R.J., Anolik, J. & Sanz, I. (2004) B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus, 13, 381-390.
59. Lu, T.Y., Ng, K.P., Cambridge, G., Leandro, M.J., Edwards, J.C., Ehrenstein, M. & Isenberg, D.A. (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis and Rheumatism, 61, 482-487.
60. Lutt, J.R., Pisculli, M.L., Weinblatt, M.E., Deodhar, A. & Winthrop, K.L. (2008) Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. Journal of Rheumatology, 35, 1683-1685.
61. Maloney, D.G., Grillo-Lopez, A.J., Bodkin, D.J., White, C.A., Liles, T.M., Royston, I., Varns, C., Rosenberg, J. & Levy, R. (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology, 15, 3266-3274.
62. Matsushita, T., Yanaba, K., Bouaziz, J.D., Fujimoto, M. & Tedder, T.F. (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. Journal of Clinical Investigation, 118, 3420-3430.
63. McDonald, V. & Leandro, M. (2009) Rituximab in non-haematological disorders of adults and its mode of action. British Journal of Haematology, 146, 233-246.
64. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
65. Molloy, E.S. & Calabrese, L.H. (2008) Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmunity Reviews, 8, 144-146.
66. Mueller, B.U., Bennett, C.M., Feldman, H.A., Bussel, J.B., Abshire, T.C., Moore, T.B., Sawaf, H., Loh, M.L., Rogers, Z.R., Glader, B.E., McCarthy, M.C., Mahoney, D.H., Olson, T.A., Feig, S.A., Lorenzana, A.N., Mentzer, W.C., Buchanan, G.R. & Neufeld, E.J. (2009) One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatric Blood & Cancer, 52, 259-262.
67. Nishio, M., Endo, T., Fujimoto, K., Sato, N., Sakai, T., Obara, M., Kumano, K., Minauchi, K. & Koike, T. (2005) Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. European Journal of Haematology, 75, 527-529.
68. Nishio, M., Fujimoto, K., Yamamoto, S., Endo, T., Sakai, T., Obara, M., Kumano, K., Minauchi, K., Yamaguchi, K., Takeda, Y., Sato, N., Koizumi, K., Mukai, M. & Koike, T. (2006) Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. European Journal of Haematology, 77, 226-232.
69. Nitta, E., Izutsu, K., Sato, T., Ota, Y., Takeuchi, K., Kamijo, A., Takahashi, K., Oshima, K., Kanda, Y., Chiba, S., Motokura, T. & Kurokawa, M. (2007) A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Annals of Oncology, 18, 364-369.
70. van Oers, M.H., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., Van't Veer, M., Vranovsky, A., Holte, H., van Glabbeke, M., Teodorovic, I., Rozewicz, C. & Hagenbeek, A. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108, 3295-3301.
71. Oren, S., Mandelboim, M., Braun-Moscovici, Y., Paran, D., Ablin, J., Litinsky, I., Comaneshter, D., Levartovsky, D., Mendelson, E., Azar, R., Wigler, I., Balbir-Gurman, A., Caspi, D. & Elkayam, O. (2008) Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Annals of the Rheumatic Diseases, 67, 937-941.
72. Palanichamy, A., Roll, P., Theiss, R., Dorner, T. & Tony, H.P. (2008) Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab. Arthritis and Rheumatism, 58, 3665-3674.
73. Perrillo, R.P. (2001) Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology, 120, 1009-1022.
74. Pescovitz, M.D. (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. American Journal of Transplantation, 6, 859-866.
75. Popa, C., Leandro, M.J., Cambridge, G. & Edwards, J.C. (2007) Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford), 46, 626-630.
76. Protheroe, A., Edwards, J.C., Simmons, A., Maclennan, K. & Selby, P. (1999) Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford), 38, 1150-1152.
77. Provan, D., Butler, T., Evangelista, M.L., Amadori, S., Newland, A.C. & Stasi, R. (2007) Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica, 92, 1695-1698.
78. Rafailidis, P.I., Kakisi, O.K., Vardakas, K. & Falagas, M.E. (2007) Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer, 109, 2182-2189.
79. Ram, R., Bonstein, L., Gafter-Gvili, A., Ben-Bassat, I., Shpilberg, O. & Raanani, P. (2009) Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. American Journal of Hematology, 84, 247-250.
80. Rao, V.K., Price, S., Perkins, K., Aldridge, P., Tretler, J., Davis, J., Dale, J.K., Gill, F., Hartman, K.R., Stork, L.C., Gnarra, D.J., Krishnamurti, L., Newburger, P.E., Puck, J. & Fleisher, T. (2009) Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood & Cancer, 52, 847-852.
81. Reynolds, J.A., Toescu, V., Yee, C.S., Prabu, A., Situnayake, D. & Gordon, C. (2009) Effects of rituximab on resistant SLE disease including lung involvement. Lupus, 18, 67-73.
82. Robinson, H. & Walker-Bone, K. (2009) Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford), 48, 448-450.
83. Roll, P., Dorner, T. & Tony, H.P. (2008) Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis and Rheumatism, 58, 1566-1575.
84. Sabath, B.F. & Major, E.O. (2002) Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. Journal of Infectious Diseases, 186(Suppl 2), S180-S186.
85. Salvi, M., Vannucchi, G., Campi, I. & Beck-Peccoz, P. (2009) Rituximab in the treatment of thyroid eye disease: science fiction? Orbit, 28, 251-255.
86. Sarrecchia, C., Cappelli, A. & Aiello, P. (2005) HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. Journal of Infection and Chemotherapy, 11, 189-191.
87. Scully, M., Cohen, H., Cavenagh, J., Benjamin, S., Starke, R., Killick, S., Mackie, I. & Machin, S.J. (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology, 136, 451-461.
88. Sfikakis, P.P., Boletis, J.N., Lionaki, S., Vigklis, V., Fragiadaki, K.G., Iniotaki, A. & Moutsopoulos, H.M. (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis and Rheumatism, 52, 501-513.
89. Sfikakis, P.P., Souliotis, V.L., Fragiadaki, K.G., Moutsopoulos, H.M., Boletis, J.N. & Theofilopoulos, A.N. (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clinical immunology, 123, 66-73.
90. Shlomchik, M.J. (2008) Sites and stages of autoreactive B cell activation and regulation. Immunity, 28, 18-28.
91. Shlomchik, M.J. (2009) Activating systemic autoimmunity: Bs, Ts, and tolls. Current Opinion in Immunology, 21, 626-633.
92. Stamenkovic, I. & Seed, B. (1988) Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein. Journal of Experimental Medicine, 167, 1975-1980.
93. Stasi, R., Pagano, A., Stipa, E. & Amadori, S. (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood, 98, 952-957.
94. Stasi, R., Del Poeta, G., Stipa, E., Evangelista, M.L., Trawinska, M.M., Cooper, N. & Amadori, S. (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood, 110, 2924-2930.
95. Stasi, R., Cooper, N., Del Poeta, G., Stipa, E., Laura Evangelista, M., Abruzzese, E. & Amadori, S. (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood, 112, 1147-1150.
96. Terrier, B., Ittah, M., Tourneur, L., Louache, F., Soumelis, V., Lavie, F., Casadevall, N., Candon, S., Hummel, A., Mariette, X. & Buzyn, A. (2007) Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica, 92, e20-e23.
97. Tesfa, D., Gelius, T., Sander, B., Kimby, E., Fadeel, B., Palmblad, J. & Hagglund, H. (2008) Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Medical Oncology, 25, 374-379.
98. Tokunaga, M., Saito, K., Kawabata, D., Imura, Y., Fujii, T., Nakayamada, S., Tsujimura, S., Nawata, M., Iwata, S., Azuma, T., Mimori, T. & Tanaka, Y. (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Annals of the Rheumatic Diseases, 66, 470-475.
99. Tsutsumi, Y., Kanamori, H., Mori, A., Tanaka, J., Asaka, M., Imamura, M. & Masauzi, N. (2005) Reactivation of hepatitis B virus with rituximab. Expert Opinion on Drug Safety, 4, 599-608.
100. Uchida, J., Lee, Y., Hasegawa, M., Liang, Y., Bradney, A., Oliver, J.A., Bowen, K., Steeber, D.A., Haas, K.M., Poe, J.C. & Tedder, T.F. (2004) Mouse CD20 expression and function. International Immunology, 16, 119-129.
101. Vallerskog, T., Gunnarsson, I., Widhe, M., Risselada, A., Klareskog, L., van Vollenhoven, R., Malmstrom, V. & Trollmo, C. (2007) Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clinical Immunology, 122, 62-74.
102. + and CD20- plasma cells in human secondary lymphoid tissue. Blood, 109, 4856-4864.
103. Yang, P.M., Su, I.J., Lai, M.Y., Huang, G.T., Hsu, H.C., Chen, D.S. & Sung, J.L. (1988) Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic type B hepatitis, with special emphasis on the activation status of the lymphocytes. American Journal of Gastroenterology, 83, 948-953.
104. Yeo, W., Chan, T.C., Leung, N.W., Lam, W.Y., Mo, F.K., Chu, M.T., Chan, H.L., Hui, E.P., Lei, K.I., Mok, T.S. & Chan, P.K. (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. Journal of Clinical Oncology, 27, 605-611.
105. Yi, J.H., Kim, S.J., Ahn, H.K., Lee, S.J., Chang, M.H. & Kim, W.S. (2009) Rituximab-induced acute thrombocytopenia: a case report and review of the literature. Medical Oncology, 26, 45-48.
106. Zaja, F., Vianelli, N., Battista, M., Sperotto, A., Patriarca, F., Tomadini, V., Fili, C., Tani, M., Baccarani, M. & Fanin, R. (2006) Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Experimental Hematology, 34, 571-572.
107. Zaja, F., Baccarani, M., Mazza, P., Vianelli, N., Bocchia, M., Gugliotta, L., Defina, M., Tieghi, A., Amadori, S., Campagna, S., Ferrara, F., De Simone, M.C., Zaccaria, A., Molinari, A.L., Angelucci, E., Usala, E., Cantoni, S., Fornaro, A., Visani, G., Rizzi, R., De Stefano, V., Casulli, F., Battista, M.L., Isola, M., Soldano, F., Regazzi, M., Gamba, E. & Fanin, R. (2008) A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in itp: results of final analysis and long term follow up. Blood (ASH Annual Meeting Abstracts), 112, 1.
108. Zingarelli, S., Airo, P., Frassi, M., Bazzani, C., Scarsi, M. & Puoti, M. (2008) Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo, 60, 22-27.